Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.58 |
| ▸ | CDC7 | O00311 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.50 |
| ▸ | CDK4 | P11802 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.44 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2919849 | 0.81 | GRM5 (0.51) | SYKCDC7GRM5RXFP1 | |
| SCHEMBL2922769 | 0.80 | SYK (0.67) | SYKCDK4CDK2 | |
| SCHEMBL2911814 | 0.80 | MAPK10 (0.53) | SYKCDC7GRM5CDK4CDK2 | |
| SCHEMBL2913599 | 0.80 | KDR (0.56) | SYKCDK4CDK2 | |
| SCHEMBL12999377 | 0.80 | ABL1 (0.58) | SYKCDK4CDK2 | |
| SCHEMBL2912369 | 0.80 | SYK (0.56) | SYKMAOBGRM5CDK4CDK2 | |
| SCHEMBL2919611 | 0.80 | L3MBTL1 (0.51) | SYKSLC2A1CDK4CDK2JAK1 | |
| SCHEMBL20752296 | 0.80 | SYK (0.65) | SYKCDC7MAOBGRM5SLC2A1 | |
| Hydrochloric Acid SCHEMBL2916265 | 0.79 | ABL1 (0.57) | SYKCDK4CDK2 | |
| SCHEMBL2920308 | 0.77 | IDH2 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009084695-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | DSTYK, ABL1, EEF2K | SYK 724/4885CDC7 405/4885MAOB 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.